WO2012032414A3 - Compositions comprenant un mélange d'huile constituée d'acides gras, un tensioactif et une statine - Google Patents

Compositions comprenant un mélange d'huile constituée d'acides gras, un tensioactif et une statine Download PDF

Info

Publication number
WO2012032414A3
WO2012032414A3 PCT/IB2011/002727 IB2011002727W WO2012032414A3 WO 2012032414 A3 WO2012032414 A3 WO 2012032414A3 IB 2011002727 W IB2011002727 W IB 2011002727W WO 2012032414 A3 WO2012032414 A3 WO 2012032414A3
Authority
WO
WIPO (PCT)
Prior art keywords
statin
surfactant
fatty acid
oil mixture
acid oil
Prior art date
Application number
PCT/IB2011/002727
Other languages
English (en)
Other versions
WO2012032414A2 (fr
Inventor
Svein Olaf Hustvedt
Preben Houlberg Olesen
Gunnar Berge
Jo Erik Johnsrud Klaveness
Original Assignee
Pronova Biopharma Norge As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pronova Biopharma Norge As filed Critical Pronova Biopharma Norge As
Publication of WO2012032414A2 publication Critical patent/WO2012032414A2/fr
Publication of WO2012032414A3 publication Critical patent/WO2012032414A3/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/107Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/20Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40Cyclodextrins; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne des préconcentrats comprenant un mélange d'huile constituée d'acides gras, au moins un tensioactif et au moins une statine ou un sel pharmaceutiquement acceptable, un hydrate, un solvate ou un complexe de celle-ci, ainsi que les utilisations de ces préconcentrats. Les préconcentrats peuvent former un système d'administration de médicament auto-nanoémulsifiant (SNEDDS), un système d'administration de médicament microémulsifiant (SMEDDS) ou des systèmes d'administration de médicament auto-émulsifiants (SEDDS) dans une solution aqueuse.
PCT/IB2011/002727 2010-09-08 2011-09-08 Compositions comprenant un mélange d'huile constituée d'acides gras, un tensioactif et une statine WO2012032414A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38107010P 2010-09-08 2010-09-08
US61/381,070 2010-09-08

Publications (2)

Publication Number Publication Date
WO2012032414A2 WO2012032414A2 (fr) 2012-03-15
WO2012032414A3 true WO2012032414A3 (fr) 2012-05-03

Family

ID=45811014

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2011/002727 WO2012032414A2 (fr) 2010-09-08 2011-09-08 Compositions comprenant un mélange d'huile constituée d'acides gras, un tensioactif et une statine

Country Status (2)

Country Link
AR (1) AR082930A1 (fr)
WO (1) WO2012032414A2 (fr)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3278665B1 (fr) 2009-04-29 2020-09-09 Amarin Pharmaceuticals Ireland Limited Composition pharmaceutique stable et procédés d'utilisation associés
AU2010241567B2 (en) 2009-04-29 2013-10-31 Amarin Pharmaceuticals Ireland Limited Pharmaceutical compositions comprising EPA and a cardiovascular agent and methods of using the same
CN108096209A (zh) 2009-06-15 2018-06-01 阿马里纳制药公司 在相伴他汀类疗法的对象中降低甘油三酯、没有增加ldl-c水平的组合物和方法
KR101798670B1 (ko) 2009-09-23 2017-11-16 아마린 코포레이션 피엘씨 오메가-3 지방산 및 스타틴의 히드록시-유도체를 포함하는 제약 조성물 및 그의 사용 방법
US11712429B2 (en) 2010-11-29 2023-08-01 Amarin Pharmaceuticals Ireland Limited Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
NZ611606A (en) 2010-11-29 2015-10-30 Amarin Pharmaceuticals Ie Ltd Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
US11291643B2 (en) 2011-11-07 2022-04-05 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
AU2013207368A1 (en) 2012-01-06 2014-07-24 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering levels of high-sensitivity (hs-CRP) in a subject
RU2633862C2 (ru) 2012-03-30 2017-10-18 Санчилио Энд Компани, Инк. Композиции сложных эфиров омега-3 жирных кислот
US10898458B2 (en) 2012-03-30 2021-01-26 Micelle Biopharma, Inc. Self-micellizing fatty acids and fatty acid ester compositions and their use in the treatment of disease states
US9480651B2 (en) 2012-03-30 2016-11-01 Sancilio & Company, Inc. Omega-3 fatty acid ester compositions unitary pharmaceutical dosage forms
US20160228397A1 (en) 2012-03-30 2016-08-11 Sancilio & Company, Inc. Omega-3 fatty acid ester compositions
KR20150036252A (ko) 2012-06-29 2015-04-07 애머린 파마슈티칼스 아일랜드 리미티드 스타틴 요법 중인 대상체에서 심혈관 사건의 위험을 감소시키는 방법
US20150265566A1 (en) 2012-11-06 2015-09-24 Amarin Pharmaceuticals Ireland Limited Compositions and Methods for Lowering Triglycerides without Raising LDL-C Levels in a Subject on Concomitant Statin Therapy
US20140187633A1 (en) 2012-12-31 2014-07-03 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
US9452151B2 (en) 2013-02-06 2016-09-27 Amarin Pharmaceuticals Ireland Limited Methods of reducing apolipoprotein C-III
US9624492B2 (en) 2013-02-13 2017-04-18 Amarin Pharmaceuticals Ireland Limited Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
US20140271841A1 (en) 2013-03-15 2014-09-18 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
US10966968B2 (en) 2013-06-06 2021-04-06 Amarin Pharmaceuticals Ireland Limited Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof
US20150065572A1 (en) 2013-09-04 2015-03-05 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing prostate cancer
US9585859B2 (en) 2013-10-10 2017-03-07 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
CA2926335C (fr) 2013-10-30 2021-11-23 Banner Life Sciences Llc Capsules enteriques molles comprenant des acides gras polyinsatures
TR201403323A2 (tr) 2014-03-21 2015-10-21 Ege Ueniversitesi Bilim Teknoloji Uygulama Ve Arastirma Merkezi Ebiltem Rosuvastatinin oral yolla kullanımı için kendiliğinden mikro/nano emülsifiye olabilen ilaç taşıyıcı sistemi.
WO2015185240A1 (fr) * 2014-06-04 2015-12-10 Sigma-Tau Industrire Farmaceutiche Riunite S.P.A. Compositions contenant de la simvastatine dans des acides gras polyinsaturés oméga-3
US10561631B2 (en) 2014-06-11 2020-02-18 Amarin Pharmaceuticals Ireland Limited Methods of reducing RLP-C
US10172818B2 (en) 2014-06-16 2019-01-08 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
US9895333B2 (en) 2014-06-26 2018-02-20 Patheon Softgels Inc. Enhanced bioavailability of polyunsaturated fatty acids
MA40846A (fr) * 2014-10-10 2017-09-05 Sancilio & Company Inc Compositions d'acides gras et d'esters d'acides gras auto-micellisantes, ainsi que leur utilisation dans le traitement d'états pathologiques
US20180015038A1 (en) * 2015-01-21 2018-01-18 Mochida Pharmaceutical Co., Ltd. Omega-3 fatty acid self-emulsifying composition
JP2019513802A (ja) * 2016-04-14 2019-05-30 ルシー マイケル 組み合わせ組成物およびその使用方法
US10966951B2 (en) 2017-05-19 2021-04-06 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject having reduced kidney function
US11058661B2 (en) 2018-03-02 2021-07-13 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L
EP3750536A1 (fr) 2018-09-24 2020-12-16 Amarin Pharmaceuticals Ireland Limited Procédés de réduction du risque d'événements cardiovasculaires chez un sujet
US11986452B2 (en) 2021-04-21 2024-05-21 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of heart failure

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5502077A (en) * 1988-08-11 1996-03-26 Norsk Hydro A.S. Fatty acid composition
WO1999029316A1 (fr) * 1997-12-10 1999-06-17 Severson, Mary, L. Compositions pharmaceutiques contenant une huile d'acide gras omega-3
WO1999056727A2 (fr) * 1998-05-07 1999-11-11 Elan Corporation, Plc Systemes d'apport de medicament de preconcentre de microemulsion et d'emulsion depourvues de solvant/cosolvant
EP1157692A1 (fr) * 2000-05-22 2001-11-28 Quatex N.V. Composition pharmaceutique d'acides gras, contenant au moins 80% en poids de EPA et DHA
US20060034815A1 (en) * 2004-08-06 2006-02-16 Hector Guzman Novel statin pharmaceutical compositions and related methods of treatment
WO2006085144A2 (fr) * 2004-10-15 2006-08-17 Photonz Corporation Limited Compositions contenant des niveaux eleves d'omega-3 et des niveaux faibles d'acides gras satures
US20060211763A1 (en) * 2005-03-08 2006-09-21 Abdel Fawzy Treatment with Statin and Omega-3 Fatty Acids and a Combination Product Thereof
US20070141138A1 (en) * 2005-12-20 2007-06-21 Cenestra Llc Omega 3 fatty acid formulations
US20080085911A1 (en) * 2006-10-10 2008-04-10 Reliant Pharmaceuticals, Inc. Statin and omega-3 fatty acids for reduction of apo-b levels
WO2010103402A1 (fr) * 2009-03-09 2010-09-16 Pronova Biopharma Norge As Compositions comprenant un mélange oléagineux à base d'acides gras comportant de l'epa et du dha sous forme d'acide libre et un tensioactif, et procédés et utilisations associés
WO2011048493A1 (fr) * 2009-10-23 2011-04-28 Pronova Biopharma Norge As Capsules ou comprimés enrobés d'un mélange oléagineux d'acides gras

Patent Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5502077A (en) * 1988-08-11 1996-03-26 Norsk Hydro A.S. Fatty acid composition
WO1999029316A1 (fr) * 1997-12-10 1999-06-17 Severson, Mary, L. Compositions pharmaceutiques contenant une huile d'acide gras omega-3
WO1999056727A2 (fr) * 1998-05-07 1999-11-11 Elan Corporation, Plc Systemes d'apport de medicament de preconcentre de microemulsion et d'emulsion depourvues de solvant/cosolvant
EP1157692A1 (fr) * 2000-05-22 2001-11-28 Quatex N.V. Composition pharmaceutique d'acides gras, contenant au moins 80% en poids de EPA et DHA
US20060034815A1 (en) * 2004-08-06 2006-02-16 Hector Guzman Novel statin pharmaceutical compositions and related methods of treatment
WO2006085144A2 (fr) * 2004-10-15 2006-08-17 Photonz Corporation Limited Compositions contenant des niveaux eleves d'omega-3 et des niveaux faibles d'acides gras satures
US20060211763A1 (en) * 2005-03-08 2006-09-21 Abdel Fawzy Treatment with Statin and Omega-3 Fatty Acids and a Combination Product Thereof
US20070141138A1 (en) * 2005-12-20 2007-06-21 Cenestra Llc Omega 3 fatty acid formulations
US20080085911A1 (en) * 2006-10-10 2008-04-10 Reliant Pharmaceuticals, Inc. Statin and omega-3 fatty acids for reduction of apo-b levels
WO2010103402A1 (fr) * 2009-03-09 2010-09-16 Pronova Biopharma Norge As Compositions comprenant un mélange oléagineux à base d'acides gras comportant de l'epa et du dha sous forme d'acide libre et un tensioactif, et procédés et utilisations associés
WO2010103404A1 (fr) * 2009-03-09 2010-09-16 Pronova Biopharma Norge As Compositions comprenant un mélange d'huile d'acide gras et d'agent tensio-actif, et leurs procédés et utilisations
WO2010119319A1 (fr) * 2009-03-09 2010-10-21 Pronova Biopharma Norge As Compositions comprenant un mélange oléagineux à base d'acides gras et d'un acide gras libre, et procédés et utilisations associés
WO2011048493A1 (fr) * 2009-10-23 2011-04-28 Pronova Biopharma Norge As Capsules ou comprimés enrobés d'un mélange oléagineux d'acides gras

Also Published As

Publication number Publication date
WO2012032414A2 (fr) 2012-03-15
AR082930A1 (es) 2013-01-16

Similar Documents

Publication Publication Date Title
WO2012032414A3 (fr) Compositions comprenant un mélange d'huile constituée d'acides gras, un tensioactif et une statine
WO2012032415A3 (fr) Compositions comprenant un mélange d'huile constituée d'acides gras comprenant epa et dha sous forme d'acide libre, un tensioactif et une statine
WO2012032417A3 (fr) Compositions comprenant un mélange d'huiles d'acides gras, un acide gras libre et une statine
IL180597A0 (en) Pharmaceutical multilayer tablet for controlled release of active ingredients with highly ph-dependent solubility
WO2012021715A3 (fr) Formulations stables de linaclotide
PH12019500030A1 (en) Compositions comprising a fatty acid oil mixture and a surfactant, and methods and uses thereof
IN2014MN02213A (fr)
WO2009085990A3 (fr) Procédés de préparation de sitagliptine et sels pharmaceutiquement acceptables de celle-ci
DE602007013611D1 (fr)
TW200744665A (en) Vitamin E succinate stabilized pharmaceutical compositions, methods for the preparation and the use thereof
WO2011041694A3 (fr) Composés utiles comme antagonistes du récepteur de l'acide lysophosphatidique (lpa)
WO2011017350A3 (fr) Composés en tant qu'antagonistes du récepteur de l'acide lysophosphatidique
WO2011080148A3 (fr) Nanosuspension intraveineuse aqueuse ayant des effets indésirables réduits
NZ748572A (en) Pharmaceutical compositions having improved storage stability
WO2010070449A3 (fr) Laquinimode très pur ou sel pharmaceutiquement acceptable de celui-ci
PL2046292T3 (pl) Preparaty eterów benzymidazolilo-pirydylowych
WO2011019326A3 (fr) Formulation pharmaceutique permettant d'augmenter la solubilité et la stabilité
WO2009060952A1 (fr) Nouvelle préparation
WO2008001201A3 (fr) Compositions pharmaceutiques de clopidogrel
MX2012001691A (es) Composiciones de linaclotida que se desintegran oralmente.
JO3587B1 (ar) أشكال جرعات بينداموستين عن طريق الفم
WO2010148314A3 (fr) Préparation d'ésoméprazole et de ses sels pharmaceutiquement acceptables
WO2012054093A3 (fr) Inhibiteurs d'acyl pipéridine d'époxyde hydrolase soluble
WO2011103920A3 (fr) Formule pharmaceutique ou nutraceutique
WO2011100838A8 (fr) Dérivés de 1-phényl-1,5-dihydro-benzo[b] [1.4]diazépine-2.4-dione en tant qu'inhibiteurs de la réplication du vih

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11823129

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11823129

Country of ref document: EP

Kind code of ref document: A2